ASPREE-XT: follow-up aspirin & ageing research
Thanks to a funding boost from the NIA (National Institute on Aging), we are delighted to announce that study visits will continue in 2018 as part of the new ASPREE-XT ( XT is shortened for eXTension) study.
A staggering 95% of ASPREE participants had indicated, prior to the end of ASPREE in December 2017, that they wanted to be part of a related follow up study.
ASPREE-XT is an observational study to investigate if there are possible long term health benefits following a period of being on low dose aspirin.
Recent studies suggest that taking aspirin for 4 – 5 years may reduce the incidence and spread of some cancers, such as bowel cancer, however this may not be evident until many years later.
ASPREE-XT will help determine possible long term effects of aspirin on cancer and other diseases associated with ageing.
It is thought that aspirin’s anti-inflammatory properties may help delay the onset or progress of some diseases over a long period. However, this theory has not been proven.
ASPREE-XT is more than an aspirin study; it is a golden opportunity to understand factors that, in the long term, affect quality of life.
In addition to the aspirin question, ASPREE-XT also aims to identify the impact that medical conditions, lifestyle, the environment and genetics have on an older person’s thinking and memory and physical function.
Because ASPREE-XT builds on existing high quality data collected in the ASPREE study, only ASPREE participants are eligible to enrol. The face-to face annual study visits will be shorter, with only one thinking and memory exercise (this will please lots of participants!). There will be no study tablets to take, no fasting blood test and phone calls will be six monthly. We hope to continue to hold these visits at the participant’s GP clinic or a community venue. Whatever their circumstance, we will try to see participants in person.
Their participation will contribute consistent, ‘real world’ health information to this research. Sharing their experience of ageing (in wellness or illness) will in turn inform the medical care given to future generations to help them maintain quality of life.
Participants will likely see familiar faces at XT study visits and hear a familiar voice on the other end of the phone – most of the ASPREE research team have stayed on to work on the ASPREE-XT project.
It is anticipated that ASPREE-XT will run for five years in Australia and the US. Our investigators are applying for funding to continue face-to-face ASPREE-XT study visits until 2022.
For further information please contact our team on 1800 728 745 (toll free from a landline).